慢性肾病与替尔泊肽在射血分数保留的心衰合并肥胖患者中的相互作用:SUMMIT 试验
SUMMIT 试验随机分配 731 例 HFpEF 且 BMI≥30 kg/m2、并富集 CKD 的患者,接受安慰剂或替尔泊肽中位 104 周。CKD 患者心衰更重、恶化心衰事件风险约增加 2 倍,但不影响替尔泊肽降低主要不良心衰事件相对风险及改善 KCCQ-CSS 等获益;替尔泊肽 52 周时经肌酐与胱抑素 C 评估的 eGFR 均升高,但个体间不一致明显。
要点
- CKD 不影响替尔泊肽降低主要不良心衰事件相对风险及改善 KCCQ-CSS 的疗效。
- CKD 患者绝对风险下降数值更大,提示该人群可能获益更多。
- 肥胖患者 eGFR 评估受脂肪与肌肉量影响,肌酐与胱抑素 C 结果可能不一致。
核心结论
- 肥胖、HFpEF 与 CKD 三联征患者功能受损明显、预后不良,但仍对替尔泊肽反应良好。
- 长期替尔泊肽经胱抑素 C 和肌酐评估均改善肾功能,但肥胖患者 eGFR 测量可能受脂肪与肌肉量及体成分变化影响而偏倚。
研究设计与样本
- SUMMIT 试验随机分配 731 例 HFpEF 且 BMI≥30 kg/m2 的患者,并富集 CKD 参与者。
- 患者接受安慰剂或替尔泊肽,中位治疗 104 周,随访心血管死亡或心衰恶化事件及 52 周 KCCQ-CSS 变化。
- eGFR 在随机化时及第 12、24、52 周分别用肌酐和胱抑素 C 公式评估。
主要发现
- 基于肌酐或胱抑素 C 定义的 CKD 患者心衰更重:功能分级、KCCQ-CSS 和 6 分钟步行距离更差,NT-proBNP 和心肌肌钙蛋白 T 更高。
- CKD 患者恶化心衰事件风险增加 2 倍。
- CKD 未影响替尔泊肽降低主要不良心衰事件相对风险及改善 KCCQ-CSS、生活质量和功能能力的效应,但主要事件绝对风险下降在 CKD 患者中数值更大。
- 基线 eGFR-胱抑素 C 较 eGFR-肌酐持续低约 9 mL/min/1.73 m2,个体差异显著。
- 替尔泊肽 52 周时经肌酐和胱抑素 C 公式评估的 eGFR 均升高,但个体患者间不一致明显;12 周时 eGFR-肌酐下降而 eGFR-胱抑素 C 未下降,52 周时胱抑素 C 评估所有患者 eGFR 改善、肌酐评估仅 CKD 患者改善。
临床怎么用
- 对肥胖相关 HFpEF 合并 CKD 患者,替尔泊肽仍可考虑用于降低心衰事件风险和改善症状。
- 接受肠促胰素类药物的肥胖患者评估肾功能时,应警惕肌酐与胱抑素 C 结果不一致,必要时联合使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity leads to both heart failure with a preserved ejection fraction (HFpEF) and to chronic kidney disease (CKD); CKD may both influence the clinical course of obesity-related HFpEF; and incretin-based drugs may influence renal function. OBJECTIVES: This analysis had dual objectives: 1) to evaluate the influence of CKD on the clinical responses to tirzepatide in patients with obesity-related HFpEF; and 2) to investigate the complexity of tirzepatide-related changes in renal function. For both objectives, we focused on discrepancies between creatinine-based and cystatin C-based estimates of the estimated glomerular filtration rate (eGFR). METHODS: The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD. Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks. Because of the confounding produced by obesity and changes in muscle mass, eGFR was assessed at randomization and after 12, 24, and 52 weeks by both creatinine-based and cystatin C-based formulae. RESULTS: Patients with CKD (based on creatinine or cystatin C) had greater severity of heart failure, as reflected by: 1) worse functional class, KCCQ-CSS scores, and 6-minute walk distance; 2) higher levels of NT-proBNP and cardiac troponin T; and 3) a 2-fold increase in the risk of worsening heart failure events. CKD did not influence the effect of tirzepatide to reduce the relative risk of major adverse heart failure events and to improve KCCQ-CSS, quality of life, and functional capacity, but the absolute risk reduction in the primary events was numerically greater in patients with CKD. Regarding renal function assessments, baseline eGFR-cystatin C was consistently ≈9 mL/min/1.73 m2 lower than that eGFR-creatinine, with significant individual variance. Furthermore, tirzepatide increased eGFR at 52 weeks, assessed by both creatinine-based and cystatin C-based formulae, but with considerable discordance in individual patients. Tirzepatide produced a decline in eGFR at 12 weeks with eGFR-creatinine (but not eGFR-cystatin C), and it led to an improvement in eGFR at 52 weeks in all patients (when assessed by cystatin C), but only in patients with CKD (when assessed by eGFR-creatinine). CONCLUSIONS: The triad of obesity, HFpEF, and CKD identifies patients with considerable functional impairment and an unfavorable prognosis, who nevertheless respond favorably to tirzepatide. Long-term tirzepatide improves renal function (both by cystatin C and creatinine), but the measurement of eGFR in patients with obesity receiving incretin-based drugs is likely to be skewed by the effects of fat and muscle mass (and by changes in body composition) on the synthesis of both cystatin C and creatinine. (A Study of Tirzepatide [LY3298176] in Participants With Heart Failure With Preserved Ejection Fraction [HFpEF] and Obesity: The SUMMIT Trial; NCT04847557).
引用
- Packer, Zile, Kramer, et al. Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial. J Am Coll Cardiol. 2025. PMID: 40162940. doi:10.1016/j.jacc.2025.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。